FIL Ltd reduced its position in Humana Inc. (NYSE:HUM - Free Report) by 37.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,958 shares of the insurance provider's stock after selling 46,876 shares during the quarter. FIL Ltd owned approximately 0.07% of Humana worth $20,286,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after acquiring an additional 1,751,857 shares during the period. Pzena Investment Management LLC boosted its stake in shares of Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after buying an additional 1,103,132 shares during the period. Geode Capital Management LLC grew its position in shares of Humana by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after buying an additional 63,562 shares in the last quarter. Invesco Ltd. increased its stake in shares of Humana by 29.8% during the fourth quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock worth $608,348,000 after buying an additional 550,692 shares during the period. Finally, Norges Bank acquired a new stake in Humana in the fourth quarter valued at approximately $416,202,000. Hedge funds and other institutional investors own 92.38% of the company's stock.
Humana Price Performance
Shares of Humana stock traded down $19.02 during trading on Thursday, hitting $266.59. 1,603,501 shares of the company were exchanged, compared to its average volume of 1,749,517. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a 50 day moving average price of $265.80 and a 200 day moving average price of $270.33. The stock has a market capitalization of $32.18 billion, a price-to-earnings ratio of 26.78, a P/E/G ratio of 2.05 and a beta of 0.62.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.
Humana Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.33%. Humana's dividend payout ratio (DPR) is currently 35.58%.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. Morgan Stanley dropped their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. StockNews.com raised Humana from a "hold" rating to a "buy" rating in a report on Monday, April 7th. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research report on Wednesday, January 15th. Guggenheim started coverage on Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. Finally, Mizuho upped their price target on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $284.90.
Get Our Latest Stock Report on HUM
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
